Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SeeMore vs Gadolinium for Peri-Infarct Injury
NCT02933034Phase 2Completed
- Sponsor
- Stanford University
- Start
- Apr 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EVP-1001-1 in ischemic cardiomyopathy (ICM), sponsored by Stanford University. Primary endpoint: Infarct Size of MEMRI Versus DEMRI Scans at Day 0. Started Apr 2015; status: completed.
02
Drugs
EVP-1001-1
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT02933034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933034.